Everest Organics
266.35
-2.45(-0.91%)
Market Cap₹258.62 Cr
PE Ratio44.80
IndustryHealthcare
Company Performance:
1D-0.91%
1M+14.49%
6M-34.39%
1Y-24.07%
5Y-23.70%
View Company Insightsright
More news about Everest Organics
13Nov 25
Everest Organics Reports Q2 FY2026 Profit, Announces Board Changes Amid Operational Challenges
Everest Organics, an API manufacturer, reported a significant financial turnaround for Q2 FY2026. Revenue increased by 38.99% to ₹10,022.53 crore, with a net profit of ₹59.47 crore compared to a loss in the previous year. The company announced board restructuring, including new appointments and changes in director designations. However, the company faces operational challenges, including production without necessary pollution control board approvals and disputed supplier interest claims of ₹143 lakhs. Management is addressing these issues through negotiations and pending approvals.
 no imag found
05Aug 25
Everest Organics Board Approves Key Director Re-appointments and New Company Secretary
Everest Organics Limited has re-appointed Dr. Srikakarlapudi Sirisha as Managing Director and Mr. Srikakarlapudi Harikrishna as Whole-time Director, both for three-year terms starting 2025, subject to shareholder approval. Ms. Shweta Singh has been appointed as the new Company Secretary and Compliance Officer. The company reported a significant financial turnaround in Q1 FY2026, with revenue increasing by 65.84% to ₹5,381.32 lakhs and a profit after tax of ₹140.52 lakhs, compared to a loss in the same quarter last year.
 no imag found
05Aug 25
Everest Organics Reports Profit Turnaround, Approves Key Management Reappointments
Everest Organics Limited, an API manufacturer, reported a profit of Rs 140.52 lakhs for Q1 FY2026, reversing a loss of Rs 608.96 lakhs from the previous year. Revenue from operations increased to Rs 5,381.32 lakhs. The board approved reappointments of Dr. Srikakarlapudi Sirisha as Managing Director and Mr. Srikakarlapudi Harikrishna as Whole-time Director, both for three-year terms. Ms. Shweta Singh was appointed as the new Company Secretary. The company's 32nd AGM is scheduled for September 27, 2025. Auditors raised concerns about enhanced production levels without necessary approvals from TSPCB, potentially affecting the company's going concern status. Management is addressing this issue and has applied for required approvals.
 no imag found
18Feb 25
Everest Organics Secures Korean Drug Master File Approval for Rabeprazole Sodium API
Everest Organics Limited has obtained Drug Master File (DMF) approval from Korean authorities for its Rabeprazole Sodium API on February 18, 2025. This approval allows the company to export the API, used in treating excessive stomach acid conditions, to the South Korean market. The development marks a significant milestone in Everest Organics' international expansion efforts and opens up new revenue opportunities in the Korean pharmaceutical industry.
 no imag found
Everest Organics
266.35
-2.45
(-0.91%)
1 Year Returns:-24.07%
Industry Peers
Sun Pharmaceutical
1,778.70
(+1.80%)
Divis Laboratories
6,534.00
(+1.58%)
Torrent Pharmaceuticals
4,231.50
(+1.16%)
Dr Reddys Laboratories
1,329.80
(-1.83%)
Cipla
1,317.60
(+0.85%)
Lupin
2,311.40
(+0.38%)
Mankind Pharma
2,256.80
(-0.34%)
Zydus Life Science
910.85
(-0.05%)
Aurobindo Pharma
1,396.80
(-1.81%)
Glenmark Pharmaceuticals
2,413.90
(+0.42%)